NasdaqGM:FOLDBiotechs
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio
BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics.
The deal marks a major change for Amicus Therapeutics and its commercial portfolio.
The transaction is viewed as a material event for shareholders and the wider biotechnology sector.
For investors watching Amicus Therapeutics, NasdaqGM:FOLD, the new acquisition agreement with BioMarin comes at a time when the stock is trading at $14.34. Over the past year, the share price return of 58.8% and...